Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT07339254
Official study title

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Study summary

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNon-Interventional Study

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 16, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of Southern California

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of Southern California
Interventions being studied
Other: Non-Interventional Study
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • \
  • Age ≥ 18 years.
  • \
  • Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
  • \
  • Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
  • \
  • Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.
Reasons someone may not be able to joinExclusion criteria
  • \
  • Patients is unable to consent for themselves
  • \
  • Patient has not yet completed the 1st cycle of ICI-based therapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Los Angeles General Medical CenterLos Angeles, California
  • USC / Norris Comprehensive Cancer CenterLos Angeles, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 16, 2026. Always confirm current availability with the study team.

View original record ↗